77 related articles for article (PubMed ID: 26783102)
1. Involvement of DDX6 gene in radio- and chemoresistance in glioblastoma.
Cho YJ; Kang W; Kim SH; Sa JK; Kim N; Paddison PJ; Kim M; Joo KM; Hwang YI; Nam DH
Int J Oncol; 2016 Mar; 48(3):1053-62. PubMed ID: 26783102
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S
Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370
[TBL] [Abstract][Full Text] [Related]
3. Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide.
Ning S; Knox SJ
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):197-203. PubMed ID: 15337556
[TBL] [Abstract][Full Text] [Related]
4. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
[TBL] [Abstract][Full Text] [Related]
5. YKL-40 downregulation is a key factor to overcome temozolomide resistance in a glioblastoma cell line.
Akiyama Y; Ashizawa T; Komiyama M; Miyata H; Oshita C; Omiya M; Iizuka A; Kume A; Sugino T; Hayashi N; Mitsuya K; Nakasu Y; Yamaguchi K
Oncol Rep; 2014 Jul; 32(1):159-66. PubMed ID: 24842123
[TBL] [Abstract][Full Text] [Related]
6. Pulsed versus conventional radiation therapy in combination with temozolomide in a murine orthotopic model of glioblastoma multiforme.
Lee DY; Chunta JL; Park SS; Huang J; Martinez AA; Grills IS; Krueger SA; Wilson GD; Marples B
Int J Radiat Oncol Biol Phys; 2013 Aug; 86(5):978-85. PubMed ID: 23845846
[TBL] [Abstract][Full Text] [Related]
7. Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients.
Shields LB; Shelton BJ; Shearer AJ; Chen L; Sun DA; Parsons S; Bourne TD; LaRocca R; Spalding AC
Radiat Oncol; 2015 Oct; 10():222. PubMed ID: 26520780
[TBL] [Abstract][Full Text] [Related]
8. FoxM1 Promotes Stemness and Radio-Resistance of Glioblastoma by Regulating the Master Stem Cell Regulator Sox2.
Lee Y; Kim KH; Kim DG; Cho HJ; Kim Y; Rheey J; Shin K; Seo YJ; Choi YS; Lee JI; Lee J; Joo KM; Nam DH
PLoS One; 2015; 10(10):e0137703. PubMed ID: 26444992
[TBL] [Abstract][Full Text] [Related]
9. Clinical and Genetic Factors Associated With Severe Hematological Toxicity in Glioblastoma Patients During Radiation Plus Temozolomide Treatment: A Prospective Study.
Lombardi G; Rumiato E; Bertorelle R; Saggioro D; Farina P; Della Puppa A; Zustovich F; Berti F; Sacchetto V; Marcato R; Amadori A; Zagonel V
Am J Clin Oncol; 2015 Oct; 38(5):514-9. PubMed ID: 24064758
[TBL] [Abstract][Full Text] [Related]
10. APE1/REF-1 down-regulation enhances the cytotoxic effects of temozolomide in a resistant glioblastoma cell line.
Montaldi AP; Godoy PR; Sakamoto-Hojo ET
Mutat Res Genet Toxicol Environ Mutagen; 2015 Nov; 793():19-29. PubMed ID: 26520369
[TBL] [Abstract][Full Text] [Related]
11. Combination Therapy with AKT3 and PI3KCA siRNA Enhances the Antitumor Effect of Temozolomide and Carmustine in T98G Glioblastoma Multiforme Cells.
Paul-Samojedny M; Pudełko A; Kowalczyk M; Fila-Daniłow A; Suchanek-Raif R; Borkowska P; Kowalski J
BioDrugs; 2016 Apr; 30(2):129-44. PubMed ID: 26902608
[TBL] [Abstract][Full Text] [Related]
12. [Concomitant radiotherapy with chemotherapy in patients with glioblastoma].
Benouaich-Amiel A; Simon JM; Delattre JY
Bull Cancer; 2005 Dec; 92(12):1065-72. PubMed ID: 16396752
[TBL] [Abstract][Full Text] [Related]
13. DDX6 post-transcriptionally down-regulates miR-143/145 expression through host gene NCR143/145 in cancer cells.
Iio A; Takagi T; Miki K; Naoe T; Nakayama A; Akao Y
Biochim Biophys Acta; 2013 Oct; 1829(10):1102-10. PubMed ID: 23932921
[TBL] [Abstract][Full Text] [Related]
14. Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide.
Messaoudi K; Clavreul A; Lagarce F
Drug Discov Today; 2015 Jul; 20(7):899-905. PubMed ID: 25744176
[TBL] [Abstract][Full Text] [Related]
15. Functional analysis of the 11q23.3 glioma susceptibility locus implicates PHLDB1 and DDX6 in glioma susceptibility.
Baskin R; Woods NT; Mendoza-Fandiño G; Forsyth P; Egan KM; Monteiro AN
Sci Rep; 2015 Nov; 5():17367. PubMed ID: 26610392
[TBL] [Abstract][Full Text] [Related]
16. Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells.
Happold C; Roth P; Wick W; Schmidt N; Florea AM; Silginer M; Reifenberger G; Weller M
J Neurochem; 2012 Jul; 122(2):444-55. PubMed ID: 22564186
[TBL] [Abstract][Full Text] [Related]
17. Erastin sensitizes glioblastoma cells to temozolomide by restraining xCT and cystathionine-γ-lyase function.
Chen L; Li X; Liu L; Yu B; Xue Y; Liu Y
Oncol Rep; 2015 Mar; 33(3):1465-74. PubMed ID: 25585997
[TBL] [Abstract][Full Text] [Related]
18. Effect of the STAT3 inhibitor STX-0119 on the proliferation of a temozolomide-resistant glioblastoma cell line.
Ashizawa T; Akiyama Y; Miyata H; Iizuka A; Komiyama M; Kume A; Omiya M; Sugino T; Asai A; Hayashi N; Mitsuya K; Nakasu Y; Yamaguchi K
Int J Oncol; 2014 Jul; 45(1):411-8. PubMed ID: 24820265
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors other than the performance status and age for glioblastoma multiforme: a single-institution experience.
Caloglu M; Yurut-Caloglu V; Karagol H; Bayir-Angin G; Turan FN; Uzal C
J BUON; 2009; 14(2):211-8. PubMed ID: 19650168
[TBL] [Abstract][Full Text] [Related]
20. Combined anti-Galectin-1 and anti-EGFR siRNA-loaded chitosan-lipid nanocapsules decrease temozolomide resistance in glioblastoma: in vivo evaluation.
Danhier F; Messaoudi K; Lemaire L; Benoit JP; Lagarce F
Int J Pharm; 2015 Mar; 481(1-2):154-61. PubMed ID: 25644286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
